April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
PresbyLASIK treatment for correcting presbyopia in hyperopic eyes
Author Affiliations & Notes
  • Alexandra Abdala
    Cornea and Refractive Surgery, Clínica Barraquer, Bogotá, Colombia
  • Verónica Castrillón
    Cornea and Refractive Surgery, Clínica Barraquer, Bogotá, Colombia
  • Clara Lopez de Mesa
    Cornea and Refractive Surgery, Clínica Barraquer, Bogotá, Colombia
  • Angela M Gutiérrez
    Cornea and Refractive Surgery, Clínica Barraquer, Bogotá, Colombia
  • Footnotes
    Commercial Relationships Alexandra Abdala, None; Verónica Castrillón, None; Clara Lopez de Mesa, None; Angela Gutiérrez, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1541. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alexandra Abdala, Verónica Castrillón, Clara Lopez de Mesa, Angela M Gutiérrez; PresbyLASIK treatment for correcting presbyopia in hyperopic eyes. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1541.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate binocular outcomes using central presbylasik technique in hyperopic patients for the treatment of presbyopia.

Methods: A retrospective longitudinal study was performed at the Clínica Barraquer, Bogotá - Colombia. Forty hypermetropic patients (80 eyes) underwent central Presbylasik treatment with PresbyMAX software developed by Schwind eye-tech-solutions and were assessed 10 days (n=80, 100%) and 90 days postoperatively (n=50, 62.5%). The remaining 30 patients did not attend the respective follow-up. Average patient age was 53 ± 5 years and mean preoperative manifest refractive spherical equivalent (MRSE) +1.45 ± 0.97 diopters (D). Mean preop uncorrected distance visual acuity (UDVA) was 0.45 ± 0.28 LogMAR. Preoperative uncorrected near visual acuity (UNVA) was investigated as reading speed and presented in LogRAD. The mean addition corrected was +2.38 ± 0.34 D with a UNVA of >0.48 LogRAD. Data was analyzed with the statistic program IBM SPSS V. 21.

Results: Ninety days after the refractive treatment the mean postoperative MRSE was -0.46±0.66 D (p<0.001) with an average UDVA of 0.22 ± 0.16 LogMAR. The mean postoperative UNVA at the 10 days follow-up was 0.09 ± 0.10 LogRAD and 0.16 ± 0.16 LogRAD at the 90 days follow-up (p=0.005). Patients gained on average 1.41 ± 3.82 lines in UDVA at the 10 days follow-up (57.5%), which increased to 2.44 ± 3.78 lines at the 90-days follow-up (66.0%). The loss of lines of UDVA in the first postoperative control was 27.5%, decreasing to 22.0% at the last follow-up. When analyzing the change of corneal aberrations between preoperative and postoperative results, there was a significant change in positive spherical aberration toward negative spherical aberrations. A statistical significance modification in coma was also observed (p <001). There was not a significant change in the cylinder, distance best corrected visual acuity (CDVA) and corrected near visual acuity (NBCVA).

Conclusions: In conclusion, PresbyMAX can be a therapeutic treatment option for correcting presbyopia and hyperopia. Patient selection is essential to achieve good results. Although an improvement of near and distance uncorrected visual acuity was observed, further postoperative controls and investigation is required to evaluate long-term results.

Keywords: 678 refractive surgery • 653 presbyopia  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.